key: cord-1043372-l28vi9fv
authors: Maruki, Taketomo; Iwamoto, Noriko; Kanda, Kohei; Okumura, Nobumasa; Yamada, Gen; Ishikane, Masahiro; Ujiie, Mugen; Saito, Masumichi; Fujimoto, Tsuguto; Kageyama, Tsutomu; Saito, Tomoya; Saito, Shinji; Suzuki, Tadaki; Ohmagari, Norio
title: Two cases of breakthrough SARS-CoV-2 infections caused by the Omicron variant (B.1.1.529 lineage) in international travelers to Japan
date: 2022-01-03
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab1072
sha: ddb45732e3357319d8eeca361e910952088207c5
doc_id: 1043372
cord_uid: l28vi9fv

In November 2021, the World Health Organization designated a new SARS-CoV-2 variant of concern, Omicron (PANGO lineage B.1.1.529). We report on first two cases of breakthrough COVID-19 caused by Omicron in Japan among international travelers returning from the country with undetected infection. The spread of infection by Omicron were considered.

A c c e p t e d M a n u s c r i p t 3 Background 9

Since December 2019, coronavirus disease 2019 (COVID-19) has been a major health threat 10 worldwide. On November 26, 2021, the World Health Organization (WHO) designated B.1.1.529 11 lineage of the SARS-CoV-2 as a new variant of concern (VOC), Omicron. The first known case of this 12 variant, detected in South Africa [1] , was reported to the WHO on November 24 [2] . Since then the 13 virus has spread rapidly across the globe.

[3] Preliminary evidence suggests an increased risk of 14 reinfection [4] , and recently, it has reported that Orf9b mutations outside spike in Omicron likely 15 contribute to adaptation [5] . Further clinical characterizations effective screening system of this 16 newly found VOC are urgently needed [6] . Herein, we report the first two known mild COVID-19 17 cases infected with Omicron in Japan. 18

Case 1 was a healthy male in his 30s. He had been vaccinated with two doses of mRNA-1273 19 SARS-CoV-2 five months before. He was a resident of Japan who traveled to Namibia on November 20 12. On November 27, before his departure, he was tested for SARS-CoV-2 via real-time reverse 21 transcriptase PCR (rRT-PCR) with a negative result. On November 28, he presented with a fever on 22 the airplane, and arrived at an international airport in Japan on the same day. He was tested positive 23 for SARS-CoV-2 via quantitative antigen test at the airport quarantine procedure and was isolated in 24 an isolation facility. On November 29, he was transferred to our hospital. He presented with a mild 25 fever, a cough, and a sore throat. On day 3, the results of viral genome sequencing confirmed 26 M a n u s c r i p t 4 infection with Omicron variant (GISAID Accession ID: EPI_ISL_6913953). He became afebrile on day 5 27 and improved without medication. 28

Case 2 was a healthy male in his 20s. He had been vaccinated with two doses of BNT162b2 29 mRNA COVID-19 vaccine two months before. He was a resident of Japan who traveled to Peru in late 30

October. He departed Peru on November 24 and transited via an international airport in Brazil, 31

where he stayed for approximately 30 hours according to him. Before his departure, he was tested 32 negative for SARS-CoV-2 via rRT-PCR. On November 27, he arrived at a major airport in Japan, where 33 he tested positive for SARS-CoV-2 by quantitative antigen test. The sample was sent to the National 34

November 30 (GISAID Accession ID: EPI_ISL_6914908). He was first isolated in an isolation facility 36 managed by Japanese Quarantine Stations. On November 28, he developed with a mild fever and a 37 sore throat. On November 30, he was transferred to our hospital. At admission, he already improved 38 his symptoms, and he had no symptoms after hospitalization. These two cases reported here were 39 fully vaccinated prior to onset. They had a mild clinical course and improved their symptoms without 40 medication for COVID-19 (Table 1) Table 1 ). It would also be worth pointing out that case1 patient was rapid test 69 negative on departure and became symptomatic during the flight. Thus, while pre-departure 70 screening might detect some cases of early infection, it is still a porous control approach. 71 M a n u s c r i p t 

cycle of quantification

Lym, lymphocytes; Neu, neutrophils; SARS-CoV2, severe acute respiratory syndrome

A c c e p t e d M a n u s c r i p t